- Reduced erythrocyte deformability in some hematological diseases: how this can affect the primary hyperviscosity syndromes (PHS) classification. [Review]Acta Haematol. 2026 Oct 27; :1. [Online ahead of print]AH
- The classification of Roe Wells formulated in 1970 and published on The New England Journal of Medicine distinguishes the primary hyperviscosity syndromes (PHS) in syndrome of polycythemic hyperviscosity, in syndrome of serum hyperviscosity and in syndrome of sclerocythemic hyperviscosity. In polycythemia vera (PV), multiple myeloma (MM), Waldenström's macroglobulinemia(WM), and monoclonal gammop…
- Publisher Full Text (DOI)
- The validation of simplified comorbidity index for predicting non-relapse mortality after allogeneic haematopoietic cell transplantation. [Journal Article]Acta Haematol. 2026 Oct 23; :1. [Online ahead of print]AH
- CONCLUSIONS: SCI score of ≥3 predicted increased NRM and decreased OS following HCT. The Revised SCI provided a hypothesis-generating basis for future prospective validation in independent cohorts.
- Publisher Full Text (DOI)
- Lactoferrin as a Natural Modulator of Immunity and Iron Homeostasis: A Review of Current Knowledge. [Review]Acta Haematol. 2026 Oct 10; :1. [Online ahead of print]AH
- CONCLUSIONS: This review summarizes the current knowledge regarding lactoferrin as a modulator of immunity and iron homeostasis, with an emphasis on recent experimental and clinical findings. Key results indicate that lactoferrin regulates NF-κB-mediated inflammation and the IL-6-hepcidin-ferroportin pathway, both of which are central to iron-restricted erythropoiesis. This review details how lactoferrin influences cytokine signaling, leukocyte function, and mucosal-microbiota interactions, which are relevant to iron sequestration and intestinal iron handling. Clinically, studies support the efficacy and tolerability of lactoferrin in iron deficiency anemia and anemia of inflammation, with outcomes varying according to the formulation, dosing, and duration. This review identifies the need for standardized biomarkers and harmonized endpoints for future research.(i) Lactoferrin may influence immunity and iron availability in inflammatory anemia. (ii) Key pathways are NF-κB signaling and IL-6-hepcidin-ferroportin axis. (iii) Clinical results show that lactoferrin can improve hematological indices and shows good overall tolerability. (iv) Evidence derives from high-risk-of-bias or very small studies. (v) Therefore, there is a need for improved clinical trials with standardized endpoints and biomarkers.
- Publisher Full Text (DOI)
- Clinical Features and Prognostic Impact of Splicing Factor Mutations and Their Co-Mutations in Acute Myeloid Leukemia. [Journal Article]Acta Haematol. 2026 Oct 10; :1. [Online ahead of print]AH
- CONCLUSIONS: SF mutations define a clinically distinct subgroup of newly diagnosed adult de novo AML characterized by adverse co-mutation profiles, lower remission rates, and inferior survival. Their adverse prognostic effect was most evident among patients receiving non-intensive therapy, although no significant interaction with treatment intensity was observed. The prognostic implications of individual SF co-mutation patterns require validation in larger independent cohorts.
- Publisher Full Text (DOI)
- Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison. [Journal Article]Acta Haematol. 2026 Oct 07; :1. [Online ahead of print]AH
- CONCLUSIONS: Oral HMAs demonstrated cytopenia severity and adverse event rates comparable to IV HMAs, supporting oral formulations as a practical alternative in patients with MDS and AML. Although encouraging, these findings should be interpreted in the context of the retrospective design and modest sample size.
- Publisher Full Text (DOI)
- Navigating the Immune Landscape: Balancing Efficacy and Toxicity of B-Cell Maturation Antigen-Targeting Agents in Multiple Myeloma. [Review]Acta Haematol. 2026 Oct 05; :1. [Online ahead of print]AH
- CONCLUSIONS: This review synthesizes current evidence on balancing the efficacy and toxicity of BCMA-targeted therapies. It details the mechanisms driving key immune-related toxicities including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome and delayed neurotoxicities. It also explores major resistance pathways such as BCMA antigen loss via genomic deletion or γ-secretase-mediated shedding. The article further evaluates risk-stratified management framework and discusses strategies to overcome resistance.Optimizing the sequencing of BCMA-directed therapies, along with developing novel combination and multi-targeting strategies, is critical to improving long-term outcomes in RRMM.
- Publisher Full Text (DOI)
- Global Disparities in Multiple Myeloma Quality of Care Indicators and Their Association with Socioeconomic Development and Behavioral Risk Factors: An Analysis of GBD 2021 Data. [Journal Article]Acta Haematol. 2026 Oct 01; :1. [Online ahead of print]AH
- CONCLUSIONS: While our findings reveal substantial gains in MM care quality, they also underscore the critical need for heightened attention to regions with high dietary risks, particularly those with lower SDI. These ecological correlations warrant confirmation in individual-level studies.
- Publisher Full Text (DOI)
- Post-Marketing Safety of the Menin Inhibitor Revumenib: A Bayesian Disproportionality Analysis of a National Database. [Journal Article]Acta Haematol. 2026 Sep 30; :1. [Online ahead of print]AH
- CONCLUSIONS: Post-marketing reporting corroborates the safety profile established in AUGMENT-101 and identifies no novel toxicity category.
- Publisher Full Text (DOI)
- Helicobacter pylori in Haematology: Contextualising Established and Emerging Associations. [Letter]Acta Haematol. 2026 Sep 21; :1. [Online ahead of print]AH
- Publisher Full Text (DOI)
- The Prevalence and Clinical Impact of Bone Marrow Fibrosis in Chronic Myeloid Leukemia. [Journal Article]Acta Haematol. 2026 Sep 17; :1-6. [Online ahead of print]AH
- CONCLUSIONS: Low-grade bone marrow fibrosis is prevalent at CML diagnosis but is not associated with the achievement of MR4.0 or sustained TFR.
- Publisher Full Text (DOI)
- Impact of Helicobacter pylori Infection on Severe Haematological Disorders. [Letter]Acta Haematol. 2026 Sep 12; :1. [Online ahead of print]AH
- Publisher Full Text (DOI)
- T-Cell Leukemia Cell Line Harboring Previously Undescribed CBFB::MYL11 Fusion Exhibits a Genome Profile Implicating Cytoskeletal Abnormality. [Journal Article]Acta Haematol. 2026 Sep 11; :1. [Online ahead of print]AH
- CONCLUSIONS: This study underscores the pathological significance of cytoskeletal abnormalities in leukemia with CBFB/myosin fusion and provides a foundation for further investigation into their molecular mechanisms.
- Publisher Full Text (DOI)
- Inferior Survival in Therapy-Related Chronic Myelomonocytic Leukemia: A Population-Based Analysis. [Journal Article]Acta Haematol. 2026 Sep 09; :1. [Online ahead of print]AH
- CONCLUSIONS: Registry-defined t-CMML was associated with inferior survival compared with de novo disease. Although chemotherapy-exposed t-CMML was associated with poorer outcomes relative to dnCMML, OS did not differ significantly between chemotherapy-exposed and radiotherapy-only patients in direct pooled or malignancy-specific comparisons. Studies integrating detailed treatment histories with molecular and cytogenetic data are needed to clarify the biology and prognostic significance of t-CMML.
- Publisher Full Text (DOI)
- Complete Remission to Imatinib in a Myeloid Neoplasm with Basophilia and PRKG2::PDGFRA Gene Fusion: A Case Report. [Case Reports]Acta Haematol. 2026 Sep 05; :1. [Online ahead of print]AH
- CONCLUSIONS: In patients with myeloproliferative features, the absence of peripheral blood eosinophilia does not rule out MLN with tyrosine kinase gene fusions. Next-generation sequencing panels that detect RNA fusions may help uncover cryptic or rare fusions. MLN with PDGFRA rearrangement responds well to imatinib.
- Publisher Full Text (DOI)
- Positive Anti-Neutrophil Antibodies Test in Autoimmune Neutropenia Experience from Single-Center Cohort. [Journal Article]Acta Haematol. 2026 Aug 26; :1. [Online ahead of print]AH
- CONCLUSIONS: Our findings suggest that adult AIN follows a benign course, similar to that of matched cohort. We also did not find any major difference between antibody-positive and -negative patients, raising questions about the utility of anti-neutrophil antibody testing in adults.
- Publisher Full Text (DOI)